Sodium phenylbutyrate

Drug Profile

Sodium phenylbutyrate

Alternative Names: Ammonaps; Buphenyl; CMK 304

Latest Information Update: 13 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ucyclyd Pharma
  • Developer CMIC; Swedish Orphan Biovitrum; Ucyclyd Pharma
  • Class Antineoplastics; Electrolytes; Phenylbutyrates; Small molecules
  • Mechanism of Action Ammonia scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperammonaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperammonaemia

Most Recent Events

  • 07 Dec 2016 Swedish Orphan Biovitrum obtains rights to distribute and market sodium phenylbutyrate in Europe, including United Kingdom, Germany, France, Italy and Spain
  • 15 Mar 2016 Biomarkers information updated
  • 07 May 2015 Hyperion Therapeutics has been acquired by Horizon Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top